Calcitriol: a better option than vitamin D in denosumab-treated patients with kidney failure?
暂无分享,去创建一个
M. Caraglia | G. Di Lorenzo | M. Ferro | C. Buonerba | G. Palmieri | M. Rizzo | F. Perri | P. Federico | Davide Bosso | Simona Malgieri
[1] Charity L. Washam,et al. Bone metastasis: mechanisms and therapeutic opportunities , 2011, Nature Reviews Endocrinology.
[2] G. Scagliotti,et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] M. Carducci,et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study , 2011, The Lancet.
[4] Y. Fujiwara,et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] G. Block,et al. A Single-Dose Study of Denosumab in Patients With Various Degrees of Renal Impairment , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[6] G. Botti,et al. Zoledronic acid: an unending tale for an antiresorptive agent , 2010, Expert opinion on pharmacotherapy.
[7] A. Negri. Association of oral calcitriol with improved survival in non-dialysed and dialysed patients with CKD. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[8] S. Oudard,et al. Renal insufficiency in bone metastasis cancer patients: Prevalence and implications on anticancer drugs management, subgroup analysis of the IRMA study , 2007 .
[9] R. Coleman. Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity , 2006, Clinical Cancer Research.
[10] D. Brancaccio,et al. Vitamin D retains an important role in the pathogenesis and management of secondary hyperparathyroidism in chronic renal failure. , 2006, Journal of nephrology.
[11] R. Brasacchio,et al. Solitary metastases: illusion versus reality. , 2006, Seminars in radiation oncology.
[12] H. Morris,et al. The effect of calcitriol on fasting urine calcium loss and renal tubular reabsorption of calcium in patients with mild renal failure--actions of a permissive hormone. , 2005, Clinical nephrology.
[13] P. Royle,et al. Denosumab for treatment of bone metastases secondary to solid tumours: systematic review and network meta-analysis. , 2013, European journal of cancer.
[14] W. Goodman,et al. The use of 1,25-dihydroxyvitamin D3 in early renal failure. , 1992, Annual review of medicine.